ABOUT THE EVENT
Date: Thursday, September 11, 2025 8–9am PDT
Event Location: Virtual
As the demand for novel biologic drug modalities continues to rise, TCR-TCE is emerging as a promising modality. However, key challenges remain, particularly the production of soluble TCR (sTCR) and low affinity of TCRs derived from phage libraries.
Join our webinar to explore two innovative platforms designed to overcome these challenges: our groundbreaking WuXian Transient™ expression system for high-titer, high-throughput sTCR expression, and optimized TCR affinity maturation processes that achieve ~10,000-fold KD improvement. Through real-world case studies, we will demonstrate how these platforms can be seamlessly integrated to generate affinity-maturated, high-titer TCR candidates, serving as essential building blocks for next-gen TCR-TCE therapeutics.
In this webinar, you will discover:
High-titer CHO production of sTCRs (~100 mg/L) and TCR-TCE using WuXian Transient™ expression system.
Optimized TCR affinity maturation from phage, routinely improving KD by ~10,000-fold (from 10-100 μM).
Integration of high-throughput CHO expression and TCR affinity maturation processes to efficiently generate building blocks for TCR-TCEs.
Speaker:
Jiansheng Wu, Ph.D., Senior VP, Head of CRO Services
